Recently, RC001, RecoRNA’s independently developed drug candidate targeting specific neurological disease, was successfully granted for Orphan Drug Designation (ODD) by the U.S. Food and Drug Administ...

RecoRNA’s project of “ disease treatment based on RNA editing technology ” won second place in the 11th China Innovation and Entrepreneurship Competition (Guangdong · Guangzhou Competition Area).

RecoRNA completed its angel investment financing round, raising millions of USD.